Avara Pharmaceutical Services Acquires Major Sterile Manufacturing Facility and Development Center in Canada
Summary
"This acquisition represents our first entry into the Canadian market and further expands our sterile processing capability, which is in very high demand," said Timothy C. Tyson, Avaras Chairman and Chief Executive Officer."It comes with a world-class development center and a dedicated team of experts that will support us in delivering high-quality pharmaceuticals that meet or exceed customer expectations and regulatory requirements.It will bring the number of manufacturing and development sites operated by Avara worldwide to ten: two in Canada; three in the United States, including corporate headquarters; one in Puerto Rico; one in the UK; one in Ireland; one in Italy; and one in France.The Boucherville site is the biggest injectables production facility in Canada and provides a number of strategic and lifesaving medicines to the Canadian healthcare system, mostly hospitals.No impact on jobs is anticipated at the moment and Avara intends to invest in the site and pursue business development opportunities to optimize the plants utilization and expand its customer base.